2-Guanidinopentanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Guanidinopentanoic acid
• 英文别名: 2-(diaminomethylideneamino)pentanoic acid
• 化学式: C₆H₁₃N₃O₂
• 分子量: 159.19
• InChiKey: ZHVPKJSXMPRWLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• TREATMENT OF DISEASES BY EPIGENETIC REGULATION
  申请人：McLure Kevin G.

  公开号：US20130281397A1

  公开（公告）日：2013-10-24

  The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.

  本公开提供了抑制溴结构域和额外末端结构域（BET）蛋白的非天然存在的多酚化合物。所公开的组合物和方法可用于治疗和预防癌症，包括NUT中线癌、Burkitt淋巴瘤、急性髓系白血病和多发性骨髓瘤；自身免疫或炎症性疾病或症状，以及败血症。
• [EN] SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS<br/>[FR] RÉACTIFS DE MÉTHYLFORMYLE SUBSTITUÉ ET PROCÉDÉ D'UTILISATION DE CEUX-CI POUR MODIFIER DES PROPRIÉTÉS PHYSICOCHIMIQUES ET/OU PHARMACOCINÉTIQUES DE COMPOSÉS
  申请人：SPHAERA PHARMA PRIVATE LTD

  公开号：WO2012137225A1

  公开（公告）日：2012-10-11

  The present invention relates to the synthesis and application of novel chiral/ achiral substituted methyl formyl reagents to modify pharmaceutical agents and/or biologically active substances to modify the physicochemical, biological and/or pharmacokinetic properties of the resulting compounds from the unmodified original agent.

  本发明涉及合成和应用新型手性/非手性取代甲基甲酰试剂，用于修改药物和/或生物活性物质，以改变未经修改的原始试剂产生的化合物的物理化学、生物学和/或药代动力学性质。
• [EN] COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS<br/>[FR] COMPOSÉS POUR LA RÉDUCTION DE LA VISCOSITÉ DE FORMULATIONS BIOLOGIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2019050780A1

  公开（公告）日：2019-03-14

  The present invention relates to pegylated amino acid compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3A, R3B and n are as defined herein. The present invention also relates to compositions which comprise a pegylated amino acid compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in combination with a high concentration of an active biological ingredient (ABI). In embodiments of the invention, the ABI is an anti-PD-1 antibody or antigen binding fragment thereof that specifically binds human programmed death receptor 1 (PD-1). The invention further relates to methods for lowering the viscosity of an aqueous solution of a pharmaceutical composition comprising adding a compound of the invention to the solution. The invention also provides methods for treating a pathological disease or condition, such as cancer, by administering to a subject in need of such treatment a therapeutically effective amount of a pharmaceutical composition of the invention.

  本发明涉及公式（I）的聚乙二醇化氨基酸化合物及其药学上可接受的盐，其中X、R1、R2、R3A、R3B和n如本文所定义。本发明还涉及包含本发明的聚乙二醇化氨基酸化合物或其药学上可接受的盐以及药学上可接受的载体的组合物，与高浓度的活性生物成分（ABI）结合。在本发明的实施例中，ABI是特异性结合人类程序性死亡受体1（PD-1）的抗PD-1抗体或其抗原结合片段。本发明还涉及降低含有本发明化合物的药物组合物水溶液粘度的方法，包括向溶液中添加本发明的化合物。本发明还提供了治疗病理性疾病或病况（如癌症）的方法，通过向需要此类治疗的受试者投予本发明的药物组合物的治疗有效量。
• NO-RELEASING GUANIDINE-CHROMENE CONJUGATES
  申请人：Euclises Pharmaceuticals, Inc.

  公开号：US20150197500A1

  公开（公告）日：2015-07-16

  The present disclosure provides NO-releasing guanidine-chromene conjugates, having the structure of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 10 , and L are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds of Formula (I); and methods useful for healing wounds, preventing and treating cancer, or treating actinic keratosis, cystic fibrosis, acne, or a disease mediated by arginine deficiency using a compound of Formula (I).

  本公开提供NO释放的胍基-色酮共轭物，具有以下结构的化学式(I)：其中R1、R2、R3、R4、R10和L如详细说明中定义；包含至少一种化合物的药物组合物的制剂；以及使用化合物(I)治愈伤口、预防和治疗癌症、或治疗日光性角化症、囊性纤维化、痤疮或由精氨酸缺乏介导的疾病的有用方法。
• Arginine Derivatives with NP-I Antagonistic Activity
  申请人：Jia Haiyan

  公开号：US20100022525A1

  公开（公告）日：2010-01-28

  The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.

  本发明涉及一种化合物，其化学式为(I)或(II)，适用于作为NP-1拮抗剂。